Merck’s Incredible Quest for the COVID-19 Blockbuster: A Tainted Path to Early Onset Mild-to-Moderate COVID-19 Therapy?

Merck’s Incredible Quest for the COVID-19 Blockbuster A Tainted Path to Early Onset Mild-to-Moderate COVID-19 Therapy

Merck’s quest for the development of treatments targeting COVID-19 has increasingly disappointed all, but the big bet stands right before them—and all of society. If this great American pharmaceutical company can successfully bring Molnupiravir (EIDD-2801) to market under emergency use authorization (EUA) by second half of 2021, they will own what could be a $5+ billion per annum market in America alone. That’s because there is no safe and efficacious treatment recognized by authorities for early onset, mild-to-moderate COVID-19—representing 90% of all coronavirus cases. Merck’s trials and tribulations during COVID-19 could be rectified, with investor praise and consumer thanks, should they ultimately prove success. But it's been a tortious process, and they are by no means close to the Land of Oz—the yellow brick drug development road is perilous, too. They have done much for humanity from the development of incredible cancer drugs to inspirational humanitarian acts, such as the donation of billions of doses of ivermectin (Stromectol/Mectizan) to the developing world, which was a great gift fighting tropical-based parasite disease. Merck notes that their ivermectin program “reach...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee